

### AMENDMENTS TO THE CLAIMS

The following listing of the claims replaces all prior versions of the claims presented in the application.

1. (Currently amended) A method of treating ~~neuromuscular dysfunction of the lower urinary tract~~ urinary incontinence in a mammal in need of such treatment comprising administering to said mammal an effective amount of ~~a compound having selective affinity for the mGlu5 subtype of the metabotropic glutamate receptors~~ 3-(2-methylthiazol-4-yl)ethynylpyridine (MTEP) in combination with an antimuscarinic drug to treat said urinary incontinence ~~neuromuscular dysfunction of the lower urinary tract~~.

2-10. (Cancelled)

11. (Currently amended) The method of claim 1 wherein said MTEP compound is administered as a pharmaceutically acceptable composition.

12. (Currently amended) The method of claim 11 wherein said MTEP compound is administered via an oral, parenteral, intranasal, sublingual, rectal or inhalatory route, or by insufflation, transdermal patches or lyophilized composition.

13. (Currently amended) The method of claims 1 wherein said MTEP compound is administered in an amount of between about 0.01 to about 25 mg/kg/day.

14. (Currently amended) The method of claim 13 wherein said MTEP compound is administered in an amount of between about 0.1 to about 10 mg/kg/day.

15. (Currently amended) The method of claim 14 wherein said MTEP compound is administered in an amount of about 0.2 to about 5 mg/kg/day.

16. (Currently amended) The method of claim 1 wherein said MTEP compound is administered at a total daily dose of about 25 to about 1000 mg.

17. (Currently amended) The method of claim 16 wherein said MTEP compound is administered at a total daily dose of about 150 to about 500 mg.

18. (Currently amended) The method of claim 17 wherein said MTEP compound is administered at a total daily dose of about 350 mg.

19. (Cancelled)

20. (Currently amended) The method of ~~claim 1~~ ~~claim 19~~ wherein said antimuscarinic drug is selected from the group consisting of oxybutynin, tolterodine, darifenacin and temiverine.

21-27. (Cancelled)

28. (Original) The method of claim 1 wherein said mammal is a human.

29. (Currently amended) The method of claim 1 wherein said MTEP compound is administered in admixture with a pharmaceutically acceptable diluent or carrier.

30. (Original) The method of claim 29 wherein said pharmaceutically acceptable diluent or carrier is selected from the group consisting of ethanol, water, glycerol, aloe vera gel, allantoin, glycerine, vitamin A oil, vitamin E oil, mineral oil, phosphate buffered saline, PPG2 myristyl propionate, magnesium carbonate, potassium phosphate, vegetable oil, animal oil, and solketal.

31-58. (Cancelled)